12-Jun-2026
Citrini sees new upside in healthcare stocks, updates basket
Seeking Alpha News (Tue, 9-Jun 11:41 AM ET)
BD Delivers Kidney Stone Care for Urology Teams with the Elyra Thulium Fiber Laser System
PRNewswire (Thu, 21-May 6:50 AM ET)
Peter Menziuso Named EVP and President, BD Interventional
PRNewswire (Mon, 18-May 6:50 AM ET)
Vitor Roque Named BD’s New CFO—Leadership Experience Signals Drive for Growth
Market Chameleon (Thu, 7-May 5:16 AM ET)
BD Appoints Vitor Roque Chief Financial Officer
PRNewswire (Thu, 7-May 6:31 AM ET)
BD Reports Second Quarter Fiscal 2026 Financial Results
PRNewswire (Thu, 7-May 6:30 AM ET)
BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI
PRNewswire (Tue, 5-May 6:50 AM ET)
BD Achieves Excellence in Employee Well-Being, Earning Top Industry Recognition
PRNewswire (Thu, 30-Apr 6:50 AM ET)
PRNewswire (Wed, 29-Apr 6:50 AM ET)
PRNewswire (Tue, 28-Apr 4:15 PM ET)
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of June 12, 2026, BDX stock price declined to $146.24 with 1,806,096 million shares trading.
BDX has a beta of 0.62, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.10 to the broad based SPY ETF.
BDX has a market cap of $41.60 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $2.90 earnings per share. This beat revenue expectation by $43 million and exceeded earnings estimates by $.13.
In the last 3 years, BDX traded as high as $287.32 and as low as $141.82.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BDX has underperformed the market in the last year with a return of +11.7%, while the SPY ETF gained +24.1%. In the last 3 month period, BDX fell short of the market, returning -7.7%, while SPY returned +11.6%. However, in the most recent 2 weeks BDX has outperformed the stock market by returning +0.1%, while SPY returned -1.9%.
BDX support price is $144.92 and resistance is $149.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.